Cenci, Tonia
 Distribuzione geografica
Continente #
NA - Nord America 4.072
EU - Europa 3.324
AS - Asia 3.067
SA - Sud America 505
AF - Africa 91
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 11.072
Nazione #
US - Stati Uniti d'America 3.983
DE - Germania 1.346
SG - Singapore 1.237
CN - Cina 1.037
SE - Svezia 513
BR - Brasile 422
IT - Italia 327
VN - Vietnam 238
FR - Francia 235
UA - Ucraina 216
GB - Regno Unito 166
IE - Irlanda 132
IN - India 116
PL - Polonia 106
ID - Indonesia 83
FI - Finlandia 82
RU - Federazione Russa 61
TR - Turchia 60
JP - Giappone 55
HK - Hong Kong 46
MX - Messico 42
BD - Bangladesh 41
IQ - Iraq 34
AR - Argentina 28
ZA - Sudafrica 28
CA - Canada 27
NL - Olanda 27
ES - Italia 23
BE - Belgio 20
EC - Ecuador 16
LT - Lituania 15
AT - Austria 14
IR - Iran 14
MA - Marocco 13
CI - Costa d'Avorio 12
PK - Pakistan 12
KR - Corea 11
SA - Arabia Saudita 11
VE - Venezuela 10
TN - Tunisia 9
CL - Cile 8
UZ - Uzbekistan 8
CH - Svizzera 7
CO - Colombia 7
JM - Giamaica 7
NP - Nepal 7
PH - Filippine 7
AZ - Azerbaigian 6
DZ - Algeria 6
KE - Kenya 6
OM - Oman 5
PE - Perù 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
EG - Egitto 4
ET - Etiopia 4
EU - Europa 4
KW - Kuwait 4
LV - Lettonia 4
MD - Moldavia 4
RO - Romania 4
CZ - Repubblica Ceca 3
GE - Georgia 3
IL - Israele 3
JO - Giordania 3
KZ - Kazakistan 3
LK - Sri Lanka 3
NI - Nicaragua 3
NO - Norvegia 3
PT - Portogallo 3
TW - Taiwan 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GR - Grecia 2
HR - Croazia 2
KG - Kirghizistan 2
NZ - Nuova Zelanda 2
PA - Panama 2
RS - Serbia 2
SN - Senegal 2
UY - Uruguay 2
VG - Isole Vergini Britanniche 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
DK - Danimarca 1
GA - Gabon 1
GF - Guiana Francese 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
Totale 11.061
Città #
Ashburn 816
Singapore 698
Chandler 494
Hangzhou 314
San Jose 304
Beijing 180
Dublin 132
Jacksonville 132
Los Angeles 115
San Mateo 106
Nanjing 100
New York 96
Nürnberg 92
Ho Chi Minh City 87
Warsaw 87
Wilmington 84
Ann Arbor 83
Jakarta 75
Lauterbourg 74
Woodbridge 71
Houston 67
The Dalles 67
Dearborn 61
Fairfield 57
Seattle 57
Cattolica 49
Hanoi 49
Munich 49
Izmir 47
Frankfurt am Main 46
Rome 44
Tokyo 44
Milan 43
Chicago 42
Nanchang 42
Boston 41
Hong Kong 41
Helsinki 36
Moscow 36
Hefei 35
Lawrence 35
Princeton 33
São Paulo 33
Bremen 29
Hyderabad 29
Redwood City 29
Council Bluffs 26
Kunming 26
Redmond 25
Marseille 24
Orem 24
Shanghai 23
Stockholm 22
Santa Clara 21
Paris 20
Shenyang 19
Lancaster 18
Mountain View 18
Brussels 17
Dallas 16
Johannesburg 16
Buffalo 15
Cambridge 15
Guangzhou 15
Hebei 15
London 15
Baghdad 14
Denver 14
Norwalk 14
Tianjin 14
Jiaxing 13
Abidjan 12
Changsha 12
Phoenix 12
Boardman 11
Haiphong 11
Kraków 11
Leawood 11
Nuremberg 11
Poplar 11
Porto Alegre 11
Seoul 11
Dhaka 10
Kent 10
Manchester 10
Rio de Janeiro 10
Zhengzhou 10
Augusta 9
Brooklyn 9
Chennai 9
Düsseldorf 9
Fremont 9
Mexico City 9
Mumbai 9
North Bergen 9
University Park 9
Vienna 9
Amsterdam 8
Hải Dương 8
Montreal 8
Totale 6.028
Nome #
Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection 614
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells 503
Diagnostic and prognostic role of HBME-1, galectin-3, and β-catenin in poorly differentiated and anaplastic thyroid carcinomas 400
C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors 320
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 304
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 252
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 233
Von hippel-lindau disease and erythrocytosis 208
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. 207
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 188
Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience 184
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. 183
PDGFRA-mutant syndrome 180
Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive 171
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. 168
Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis 167
The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma 167
Diagnostic and prognostic value of immunocytochemistry and braf mutation analysis on liquid based biopsies of thyroid neoplasms suspicious for carcinoma. 160
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 160
Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. 159
The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia 146
Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease 145
Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin 144
Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior 141
A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis 140
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 140
Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior 139
Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma 138
Expression of EGFRvIII in glioblastoma: prognostic significance revisited. 136
Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases 136
Methylation study of the Paris system for reporting urinary (TPS) categories 132
The mutant JAK2 allele burden in children with essential thrombocythemia 130
The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms 129
Dissecting Stemness in Aggressive Intracranial Meningiomas: Prognostic Role of SOX2 Expression 128
Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis 128
Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms 128
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 128
DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group 127
Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights 124
Divergent gastrointestinal stromal tumors in syndromic settings 121
Chemotherapy of Skull Base Chordoma Tailored on Responsiveness of Patient-Derived Tumor Cells to Rapamycin1,2 121
SPTBN1 Mediates the Cytoplasmic Constraint of PTTG1, Impairing Its Oncogenic Activity in Human Seminoma 120
PTTG1/ZEB1 Axis Regulates E-Cadherin Expression in Human Seminoma 120
Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis 119
Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma 119
Telomerase inhibition in malignant gliomas. A systematic review 118
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response 117
Protein Expression of PTTG-1, OCT-4, and KLF-4 in Seminoma: A Pilot Study. 117
Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms 111
Plexiform architecture in gastrointestinal stromal tumors is not restricted to succinate dehydrogenase-deficient cases 111
Epigenetic Silencing of Id4 Identifies a Glioblastoma Subgroup With a Better Prognosis as a Consequence of an Inhibition of Angiogenesis 110
Tailored therapy for recurrent glioblastoma. Report of a personalized molecular approach 110
how limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid based cytology. Role of TERT promoter and BRAF V600E mutation analysis 107
Morphology combined with ancillary techniques: An algorithm approach for thyroid nodules 105
Morphology combined with ancillary techniques: An algorithm approach for thyroid nodules 105
Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme 102
Pituitary-tumour-transforming-gene 1 expression in testicular cancer 102
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma 101
Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis 101
The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence? 100
Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples. 98
SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System 98
Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report 97
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia 96
Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas 96
The role of thyroid FNA cytology in pediatric malignant lesions: An overview of the literature 96
Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study 93
To obtain more with less cytologic samples with ancillary molecular techniques-the useful role of liquid-based cytology 92
Erratum: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells (Nature (2010) 468 (824-828)) 89
Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis 86
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response 85
The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies with Aggressive Behavior 76
Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin 69
Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive 69
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response 65
The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior 58
Totale 11.187
Categoria #
all - tutte 40.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.649


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021127 0 0 0 0 0 0 0 0 0 25 88 14
2021/2022661 70 42 16 64 57 20 16 96 28 45 87 120
2022/20231.344 196 198 101 208 93 159 54 85 155 28 47 20
2023/20241.116 27 203 25 50 16 92 265 261 6 30 65 76
2024/20251.277 32 29 119 40 106 51 44 55 179 145 255 222
2025/20263.314 490 121 193 432 660 191 659 171 236 161 0 0
Totale 11.187